Satisfaction with treatment · people with non‐transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence: Discontinuations · people with non‐transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: Discontinuations compared with placebo (low certainty).
1 finding from 1 review
AE: abnormal serum creatinine (post‐baseline) · people with non‐transfusion‐dependent thalassemia
It is very uncertain whether deferasirox changes AE: abnormal serum creatinine (post‐baseline) compared with placebo (very low certainty).
1 finding from 1 review
Participant satisfaction (very satisfied or satisfied) · people with transfusion‐dependent thalassemia
Deferasirox probably leads to higher satisfaction with treatment (very satisfied or satisfied):… compared with deferoxamine (moderate certainty).
1 finding from 1 review
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: discontinuations compared with deferoxamine (low certainty).
1 finding from 1 review
Adverse event: Isolated serum creatinine increase above upper limit of normal · people with transfusion‐dependent thalassemia
Deferasirox may leads to higher AE: investigations ‐ isolated serum creatinine increase above ULN compared with deferoxamine (low certainty).
1 finding from 1 review
Mortality at any time point · people with transfusion‐dependent thalassemia
1 finding from 1 review
Responder analysis · people with transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with managing transfusional iron overload in people with sickle cell disease
It is very uncertain whether deferasirox changes mortality compared with deferoxamine (very low certainty).
1 finding from 1 review
End‐organ damage (incidence of diabetes) · patients with managing transfusional iron overload in people with sickle cell disease
It is very uncertain whether deferasirox changes end‐organ damage (incidence of diabetes) compared with deferoxamine (very low certainty).
1 finding from 1 review
LIC · patients with managing transfusional iron overload in people with sickle cell disease
1 finding from 1 review
Ferritin (µg/L) · patients with managing transfusional iron overload in people with sickle cell disease
1 finding from 1 review
AE: Change in creatinine from baseline (µmol/l) · patients with managing transfusional iron overload in people with sickle cell disease
1 finding from 1 review
Overall discontinuation ( · patients with managing transfusional iron overload in people with sickle cell disease
Deferasirox may leads to lower discontinuations compared with deferoxamine (low certainty).
1 finding from 1 review
Satisfaction · patients with managing transfusional iron overload in people with sickle cell disease
Deferasirox probably leads to higher satisfaction compared with deferoxamine (moderate certainty).
1 finding from 1 review
Mortality at any time point · people with transfusion‐dependent thalassemia
1 finding from 1 review
Responder analysis · people with transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serum ferritin (ng/mL): mean change from baseline · people with transfusion‐dependent thalassemia
1 finding from 1 review
LIC · people with transfusion‐dependent thalassemia
1 finding from 1 review
Satisfaction · people with transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found